News
Satya Nadella has unveiled BioEmu, Microsoft's new AI initiative aimed at accelerating drug discovery processes.
TPN-101, a potent nucleoside reverse transcriptase inhibitor that specifically inhibits the LINE-1 reverse transcriptase.
Microsoft's CEO, Satya Nadella, has announced BioEmu-1, a new AI system designed to accelerate drug discovery by decoding ...
A Financial District-based drug discovery company inked a $1 billion licensing agreement with pharmaceutical giant AbbVie to develop its signature cancer drug. IGI Therapeutics SA, a subsidiary of the ...
Microsoft’s new AI system BioEmu will help decode protein motion and help in faster discovery of drugs, said CEO Satya ...
Microsoft's BioEmu, an AI-driven model, decodes protein motion to enhance drug discovery, offering rapid insights into ...
Researchers discovered how to flip the structure of complex drug compounds using a simple reagent, offering a game-changing ...
Centella AI streamlines drug discovery using AI-powered platforms, reducing R&D time and cost with real-world scientific validation ...
Drug discovery startup Synfini Inc. said today it has closed on an $8.9 million expansion funding round led by JSL Health ...
Microsoft's CEO, Satya Nadella, has introduced BioEmu-1, a new AI system designed to accelerate drug discovery by decoding protein motion.
Every protein in the body is encased in a water shell that directs protein structure, provides vital stability and steers ...
2d
rocketcitynow.com on MSNWoman on parole following past drug conviction rearrested after meth discoveryA woman paroled last fall after serving time on a multi-count drug conviction has been arrested on numerous felony counts ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results